Another promising treatment: an anti-CD20 antibody--kind of a second-generation Rituxan--that Genentech plans to test against rheumatoid arthritis, lupus and multiple sclerosis.
FORBES: Magazine Article
应用推荐
模块上移
模块下移
不移动